Michael S. Perry - 18 Aug 2026 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Reporting relationship: Director
Issuer ticker: ARWR
Reported as of: 18 Aug 2026
Net transaction value: -$1,012,680
SEC form: 4
Accepted by SEC: 20 Aug 2026, 17:22:21 UTC
Prior SEC filing: 18 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/Michael Perry

Key filing fact

Michael S. Perry filed Form 4 for ARROWHEAD PHARMACEUTICALS, INC. (ARWR) on 20 Aug 2026.

Key facts

This page summarizes Michael S. Perry's Form 4 filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Aug 2026, 17:22.

Change

Previous filing in this sequence was filed on 18 Dec 2025.
Current net transaction value: -$1,012,680.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001250379 Primary reporting owner

PERRY MICHAEL S

Relationship: Director
Address: 177 E. COLORADO BLVD, SUITE 700, PASADENA
Signature: /s/Michael Perry
Signature date: 20 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARWR transaction

Common Stock

Sale

Transaction value: $1,012,680
Shares: -11,600
Change %: -9.4%
Price: $87.30
Shares after: 111,459
Date: 18 Aug 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $87.20 to $87.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Footnote F2

Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.